The US Food and Drug Administration has approved Gilead Sciences' (GILD) Bixlenvo, a once-daily oral combination pill for adults whose HIV infection has already been suppressed to very low levels, the company said.

Kimberly-Clark (KMB) has filed for European Union regulatory approval of its proposed $40 billion acquisition of Kenvue (KVUE), according to documents published on the European Commission's website.

Eli Lilly (LLY) has agreed to acquire privately held Merida Biosciences for up to $2.88bn in cash, bolstering its immunology pipeline with an experimental treatment for thyroid-related autoimmune conditions as the company accelerates its push beyond weight-loss drugs.

BridgeBio Pharma (BBIO) has presented new analyses from its phase 3 ATTRibute-CM study of Attruby (acoramidis) in transthyretin amyloid cardiomyopathy, including the first evidence from serial cardiac magnetic resonance imaging that a therapy may be capable of reversing disease progression, at the European Society of Cardiology Congress 2026.

Novartis (NVS) has suspended eight clinical trials of its experimental cell therapy rap-cel, which targets autoimmune and neurological disorders, after three patients died following a severe immune reaction, the Swiss drugmaker disclosed.

Jazz Pharmaceuticals (JAZZ) has secured a second overall survival victory for its bispecific antibody Ziihera in HER2-positive gastroesophageal adenocarcinoma, strengthening the drug's case as the preferred treatment backbone in a condition affecting roughly 8,000 Americans annually.

Florida's attorney general has filed suit against pharmacy benefit managers Express Scripts, a unit of Cigna (CI), and Prime Therapeutics, accusing the rival drug middlemen of engaging in illegal price-fixing that has gutted reimbursements to the state's pharmacies and threatened patient access to medications.

Pharmaceutical companies have sharply accelerated their embrace of artificial intelligence, striking a wave of partnerships and acquisitions since the start of 2025 as they seek to compress drug development timelines and reduce costs through automation and advanced molecular modelling.

A US federal court has ordered Guardant Health (GH) to pay more than $245.2mn to TwinStrand Biosciences and the University of Washington after finding the cancer diagnostics company had infringed patents covering DNA sequencing technology.

Argenx SE (ARGX) has staged one of Europe's most striking biotech rallies in recent memory. The company’s dramatic gains last month have propelled the Belgian biotech’s market capitalization to €55.4bn ($64.8bn), overtaking Moderna (MRNA), whose own market value has more than doubled over the same period following its own dramatic run.

The US Food and Drug Administration has approved Gilead Sciences' (GILD) once-daily oral combination pill for the treatment of adults whose HIV infection has already been reduced to undetectable levels, the California-based drugmaker said.

Kimberly-Clark (KMB) has filed for European Union regulatory approval of its proposed $40bn acquisition of Kenvue (KVUE), according to documents published on the European Commission's website, as the consumer goods company advances its most ambitious deal in years.

The Trump administration has unveiled a second wave of drug pricing agreements under its most favored nation, or MFN, policy framework, this time securing deals with nine mid-sized pharmaceutical companies including Alcon (ALC), Astellas Pharma (ALPMY), BeOne Medicines (ONC), BridgeBio (BBIO), CSL, Kyowa Kirin (4151), Sun Pharma (SUNPHARMA), Teva Pharmaceuticals (TEVA) and UCB (UCB).

Alnylam Pharmaceuticals (ALNY) has lowered its full-year 2026 sales guidance by approximately $200mn, blaming slower-than-expected growth in its transthyretin, or TTR, amyloidosis franchise after initial launch demand normalized — a disclosure that sent the company's shares tumbling more than 28 per cent.

Celon Pharma (CLNP) said its experimental semaglutide product Reduzek demonstrated comparable absorption to Novo Nordisk's (NVO) Ozempic and Wegovy in an early-stage bioequivalence study, sending shares in the Polish drugmaker up 14.7 per cent — on course for their best single-day gain since July 2024.

The US Food and Drug Administration has cleared a blood test developed by Roche (RHHBY) and Eli Lilly (LLY) to help identify signs of Alzheimer's disease in patients aged 55 and older experiencing cognitive decline, marking another step in the industry's push to make diagnosis simpler and more accessible.

Eli Lilly (LLY) has launched Foundayo, its oral weight-loss and diabetes treatment, in the United Kingdom, making Britain the first country in Europe where the pill is available following regulatory approval earlier this month.

European regulators have laid out in greater detail the concerns underpinning their decision to strip the rare disease drug Tavneos of its marketing authorization in the European Union, alleging serious breaches of clinical trial protocol that they say fundamentally undermine the evidence base supporting the complement inhibitor.

In the private dining room of a San Francisco steakhouse in January, Albert Bourla cut a confident figure. The Pfizer (PFE) chief executive joked with reporters as he fielded questions about his company and the broader pharmaceutical landscape, his mood seemingly untouched by the pressures bearing down on the drugmaker he has led since 2019.

Karyopharm Therapeutics (KPTI) is racing to secure financing or a lender waiver before a $15.8mn loan payment falls due on September 10, after a deepening second-quarter loss left the company with just $65.4mn in cash and a runway extending only into next month.